Richter TransformationPhase 2CLLRT2NCT07917780
A Prospective, Open-label, Randomized, Multicenter Phase-III Trial to Evaluate the Efficacy of Pirtobrutinib and Epcoritamab Compared With R-(Mini)-CHOP for Treatment of Patients With DLBCL-type Richter Transformation
A Phase 2 study testing Epcoritamab, Pirtobrutinib and Cyclophosphamide in people with Richter Transformation, run by German CLL Study Group at 12 sites in 5 countries.
Trial summary
The aim of the trial is to Evaluate the Efficacy of Pirtobrutinib and Epcoritamab Compared With R-(Mini)-CHOP for Treatment of Patients With DLBCL-type Richter Transformation Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Richter Transformation
- What is being tested?
- Epcoritamab, Pirtobrutinib and Cyclophosphamide
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 116 participants
- Where
- 12 sitesin 5 countries
- Study dates
- 18 Jun 2026to 15 May 2030
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥80 years OR considered frail defined by a frailty score of >2 on the FRAIL scale via the patient´s assessment
- Has documented treatment-naïve CLL or small lymphocytic lymphoma (SLL) according to iwCLL 2018 criteria3
- CLL/SLL requiring treatment according to the iwCLL 2018 criteria3
- Adequate marrow function independent of growth factor or transfusion support within 2 weeks of screening as follows, unless cytopenia is due to marrow involvement of CLL:
- Absolute neutrophil count ≥ 1.0 × 10^9/L
- Platelet counts ≥ 30 × 10^9/L; in cases of thrombocytopenia clearly due to marrow in-volvement of CLL (per the discretion of the investigator); platelet count should be ≥ 10 × 10^9/L if there is bone marrow involvement
Show all 17Show fewer
- Total haemoglobin ≥ 9 g/dL (without transfusion support, unless anaemia is due to mar-row involvement of CLL)
- Adequate liver function as indicated by a total bilirubin, AST, and ALT ≤2 times the institutional upper limit of normal (ULN) value unless directly attributable to the patient's CLL or Gilbert's syndrome
- Adequate renal function defined by a value ≥30 mL/min, determined either by creatinine clearance directly measured with a 24-hour urine collection or via estimated GFR calculated according to the CKD-EPI equation or Cystatin C measurements (e.g. in sarcopenic patients).
- Negative serological testing for hepatitis B (HBsAg negative and anti-HBc negative; patients positive for anti-HBc may be included if PCR for HBV DNA is negative and HBV-DNA PCR is performed repeatedly until 6 months after last month of treatment), negative testing for hepa-titis C RNA within 6 weeks prior to registration
- Life expectancy ≥ 3 months
- In case of a recent previous (i.e. debulking) treatment, patients must have recovered from acute toxicities and treatment regimen must be stopped within the following time periods be-fore start of the study treatment in the CLL-Frail2 trial:
- chemotherapy ≥ 28 days
- antibody treatment ≥ 14 days
- corticosteroids may be applied until the start of the study therapy; these have to be re-duced to an equivalent of ≤ 20mg prednisolone per day during treatment
- Signed informed consent and, in the investigator's judgment, able to comply with the study protocol
- Ability and willingness to provide written informed consent and to adhere to the study visit schedule and other protocol requirements
Who cannot join
- 1. Previous CLL-directed therapies 2. Transformation of CLL to aggressive NHL (Richter's transformation or pro-lymphocytic leu-kaemia) 3. Patients with a history of confirmed progressive multifocal leukoencephalopathy (PML) 4. Uncontrolled autoimmune condition 5. Malignancies other than CLL currently requiring systemic therapies (unless the malignant dis-ease is in a stable remission at the discretion of the treating physician) 6. Uncontrolled infection currently requiring systemic treatment 7. Any serious medical condition or abnormality in clinical laboratory tests that, in the investiga-tor's judgment, precludes the patient's safe participation in and completion of the study 8. Requirement of treatment with any moderate or strong CYP3A4 inhibitor or strong CYP3A4 inducer (≤ 14 days or 5 half-lives, whichever is shorter) before the first dose of study drug, or requiring ongoing treatment with a moderate or strong CYP3A inhibitor or a strong CYP3A in-ducer.
- 9. Requirement of therapy with phenprocoumon or other vitamin K antagonists 10. Known active infection with HIV, or serologic status reflecting active hepatitis B or C infection as follows:
- Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). Patients with presence of HBcAb, but absence of HBsAg, are eligible if hepatitis B virus (HBV) DNA is undetectable (< 20 IU), and if they are willing to undergo monitoring for HBV reactivation
- Presence of hepatitis C virus (HCV) antibody. Patients with presence of HCV antibody are eligible if HCV RNA is undetectable 11. Major surgery within 4 weeks of the first dose of study drug 12. Any uncontrolled or clinically significant cardiovascular disease including the following:
- New York Heart Association class III or IV congestive heart failure
- History of clinically significant arrhythmias (eg, sustained ventricular tachycardia, ventricu-lar fibrillation, torsades de pointes) 13. History of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand dis-ease if not CLL/SLL related, or history of spontaneous bleeding requiring blood transfusion or other medical intervention 14. Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery proce-dures, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.
Show all 9Show fewer
- 15. Use of investigational agents, e.g. monoclonal antibodies or other experimental drugs within clinical trials, which might interfere with the study drug within 28 days (or 5 times half-life [t1/2] of the compound, whichever is longer) prior to registration 16. Known hypersensitivity to zanubrutinib or sonrotoclax or any of the excipients 17. Pregnant women and nursing mothers (a negative pregnancy test is required for all women of childbearing potential within 7 days before start of treatment) 18. Fertile men or women of childbearing potential unless:
- surgically sterile or ≥ 2 years after the onset of menopause, or
- willing to use two methods of reliable contraception including one highly effective contra-ceptive method (Pearl Index <1) and one additional effective (barrier) method during study treatment and for 7 days after sonrotoclax and 30 days after zanubrutinib respec-tively 19. Vaccination with a live vaccine <28 days prior to registration 20. Legal incapacity 21. Prisoners or subjects who are institutionalized by regulatory or court order 22. Persons who are in dependence to the sponsor or an investigator
Trial locations and contacts
12 sites in 5 countries. Contact the study team or a site near you to ask about taking part.
12 sites in 5 countries
Germany6 sites, 6 recruiting
- Recruiting
Uniklinik Köln
Cologne, 50937
Barbara Eichhorst, Prof., +4922147888220, barbara.eichhorst@uk-koeln.de
- Not yet recruiting
Technische Universitaet Dresden
Dresden, 01307
Johannes Schetelig, Prof., +493514585604, Johannes.Schetelig@ukdd.de
- Recruiting
Universitätsklinikum Frankfurt
Frankfurt, 60590
Sebastian Scheich, +496963013767, s.scheich@med.uni-frankfurt.de
- Not yet recruiting
Universitätsklinikum Heidelberg
Heidelberg, 69120
Peter Dreger, Prof., +496221568030, Peter.Dreger@med.uni-heidelberg.de
- Not yet recruiting
Universitätsklinikum Schleswig-Holstein Campus Kiel
Kiel, 24105
Matthias Ritgen, Dr., +4943150022555, m.ritgen@med2.uni-kiel.de
- Recruiting
Universitätsklinik Ulm
Ulm, 89081
Christof Schneider, Dr., +4973150056012, christof.schneider@uniklinik-ulm.de
Austria2 sites, 2 recruiting
- Not yet recruiting
Medizinische Universitaet Innsbruck
Innsbruck, 6020
Dominik Wolf, Prof., +4351250424003, mui-oversight@i-med.ac.at
- Recruiting
Medizinische Universität Wien
Vienna, 1090
Alexander Gaiger, +4314040044765, alexander.gaiger@meduniwien.ac.at
Ireland2 sites, 2 recruiting
- Recruiting
Beaumont Hospital
Dublin, Dublin 9
Patrick Thornton, +613 8559 5000, philip.thompson@petermac.org
- Recruiting
University Hospital Galway
Galway, H91 YR71
Amjad Hayat, +35391544281, amjad.hayat@hse.ie
Australia1 site, 1 recruiting
- Recruiting
Peter MacCallum Cancer Center
Melbourne, 3000
Philip Thompson, Prof., +613 8559 5000, philip.thompson@petermac.org
Denmark1 site, 1 recruiting
- Not yet recruiting
Rigshospitalet
Copenhagen, 2100
Caspar Da Cunha-Bang, MD, +4535450410, Caspar.Da.Cunha-Bang@regionh.dk
About this study
The aim of the trial is to Evaluate the Efficacy of Pirtobrutinib and Epcoritamab Compared With R-(Mini)-CHOP for Treatment of Patients With DLBCL-type Richter Transformation
Read the detailed description
This trial is a phase 2 study and - according to the definitions of the ICH Harmonized Tripartite Guide-line E8 - a therapeutic exploratory type of study, which is designed as a prospective, multicenter, open label trial. The trial aims to investigate the efficacy and safety of a fixed-duration treatment ap-proach in patients aged 80 years or older and/or those exhibiting symptoms of frailty.
- Conditions
- Richter Transformation
- Being tested
- Epcoritamab, Pirtobrutinib, Cyclophosphamide, Doxorubicin, Vincristine
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EpcoritamabBiological
Also called Epkinly®
Cycle 1 Day 1-21: Pirtobrutinib 200 mg QD po Day 1: Epcoritamab 0.16 mg sc Day 8: Epcoritamab 0.8 mg sc Day 15: Epcoritamab 48 mg sc
Cycle 2-28 Epcoritamab 48 mg sc
PirtobrutinibDrug
Also called Jaypirca®
Pirtobrutinib 200 mg QD po
CyclophosphamideDrug
750 mg/m2 iv (R-CHOP) or 400 mg/m2 iv (R-mini-CHOP)
DoxorubicinDrug
50 mg/m2 iv (R-CHOP) or 25 mg/m2 iv (R-mini-CHOP)
VincristineDrug
1.4 mg/m2 iv (R-CHOP) or 1 mg/m2 iv (R-mini-CHOP)
RituximabDrug
375 mg/m2 iv (R-CHOP) or 375 mg/m2 iv or sc (R-mini-CHOP)
| Study group | Role | What they receive |
|---|---|---|
| Arm A: R-(mini)-CHOP | Active comparator | Cycle 1-6 Day 1: Cyclophosphamide 750 mg/m2 iv Doxorubicin 50 mg/m2 iv Vincristine 1.4 mg/m2 (max 2 mg) iv Rituximab 375 mg/m2 iv Day 1-5: Prednisolone 100 mg po
If R-CHOP-ineligible*, R-mini-CHOP3 is administered:
Cycle 1-6 Day 1: Cyclophosphamide 400 mg/m2 iv Doxorubicin 25 mg/m2 iv Vincristine 1 mg iv Rituximab 375 mg/m2 iv or sc Day 1-5: Prednisolone 100 mg po Receives: Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Rituximab |
| Arm B: Epcoritamab-Pirtobrutinib | Experimental | 12 cycles: Cycle 1 Day 1-21: Pirtobrutinib 200 mg QD po Day 1: Epcoritamab 0.16 mg sc Day 8: Epcoritamab 0.8 mg sc Day 15: Epcoritamab 48 mg sc
Cycle 2-4 Day 1-21: Pirtobrutinib 200 mg QD po Day 1, 8, 15: Epcoritamab 48 mg sc
Cycle 5+6 Day 1-21: Pirtobrutinib 200 mg QD po Day 1: Epcoritamab 48 mg sc
Cycle 7-12:
Day 1-28: Pirtobrutinib 200 mg QD po Day 1: Epcoritamab 48 mg sc
For patients with CR, PR or SD after 12 cycles (=EO[C]T), maintenance treatment with pirtobrutinib 200 mg QD until unacceptable toxicity, disease progression or allogeneic stem cell transplantation will be offered. Receives: Biological: Epcoritamab; Drug: Pirtobrutinib |
What is being measured
The primary outcome is the main question the study is designed to answer.
PFS
Investigator-assessed progression-free survival (PFS) according to Lugano criteria
Measured: approx. 40 months after first subject in
Secondary outcomes (9)
ORR
Overall response rate (ORR) at the end of (combination) treatment according to Lugano criteria
Measured: approx. 40 months after first subject in
CRR
Complete response rate (CRR) at the end of (combination) treatment according to Lugano criteria
Measured: approx. 40 months after first subject in
Best response according to Lugano criteria
Best response according to Lugano criteria
Measured: approx. 40 months after first subject in
Undetectable minimal residual disease (uMRD)
Undetectable minimal residual disease (uMRD) rates in peripheral blood at the end of (combination) treatment
Measured: approx. 40 months after first subject in
DOR
Duration of response (DOR) according to Lugano criteria
Measured: approx. 40 months after first subject in
Overall survival (OS)
Overall survival (OS)
Measured: approx. 40 months after first subject in
TTNT
Time to next treatment (TTNT)
Measured: approx. 40 months after first subject in
TFS
Treatment-free survival (TFS)
Measured: approx. 40 months after first subject in
SCT
Proportion of patients receiving allogeneic stem cell transplantation (SCT) for consolidation
Measured: approx. 40 months after first subject in
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Nov 2026
- Study start18 Jun 2026
- Primary completion15 May 2030 (estimated)
- Study completion15 May 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Richter TransformationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- randomized (1:1) and stratified
- Masking
- None (open label)
- Enrolment
- 116 participants (estimated)
Sponsor and investigators
- Lead sponsor
- German CLL Study Group
- Sponsor type
- University, hospital or other
- Collaborators
- Cancer Trials Ireland (CTI), The Australasian Leukaemia & Lymphoma Group (ALLG), Fondazione GIMEMA, Nordic CLL Study Group (NCLLSG)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07917780
- Sponsor's protocol ID
- CLLRT2
- Acronym
- CLLRT2
- Status last verified
- Oct 2026
- First submitted
- 28 Oct 2026
- Last updated
- 5 Nov 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Open-label, Randomized, Multicenter Phase-III Trial to Evaluate the Efficacy of Pirtobrutinib and Epcoritamab Compared With R-(Mini)-CHOP for Treatment of Patients With DLBCL-type Richter Transformation
- ClinicalTrials.gov ID
- NCT07917780
- Acronym / sponsor ID
- CLLRT2 / CLLRT2
- Conditions
- Richter Transformation
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 116 participants (estimated)
- Lead sponsor
- German CLL Study GroupUniversity, hospital or other
- Collaborators
- Cancer Trials Ireland (CTI), The Australasian Leukaemia & Lymphoma Group (ALLG), Fondazione GIMEMA, Nordic CLL Study Group (NCLLSG)
- Study start
- 18 Jun 2026 (actual)
- Primary completion
- 15 May 2030 (estimated)
- Study completion
- 15 May 2030 (estimated)
- First posted
- 5 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the trial is to Evaluate the Efficacy of Pirtobrutinib and Epcoritamab Compared With R-(Mini)-CHOP for Treatment of Patients With DLBCL-type Richter Transformation
Detailed description
This trial is a phase 2 study and - according to the definitions of the ICH Harmonized Tripartite Guide-line E8 - a therapeutic exploratory type of study, which is designed as a prospective, multicenter, open label trial. The trial aims to investigate the efficacy and safety of a fixed-duration treatment ap-proach in patients aged 80 years or older and/or those exhibiting symptoms of frailty.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- randomized (1:1) and stratified
| Arm | Type | Receives |
|---|---|---|
| Arm A: R-(mini)-CHOP | Active comparator | Drug: Cyclophosphamide, Drug: Doxorubicin, Drug: Vincristine, Drug: RituximabCycle 1-6 Day 1: Cyclophosphamide 750 mg/m2 iv Doxorubicin 50 mg/m2 iv Vincristine 1.4 mg/m2 (max 2 mg) iv Rituximab 375 mg/m2 iv Day 1-5: Prednisolone 100 mg po If R-CHOP-ineligible*, R-mini-CHOP3 is administered: Cycle 1-6 Day 1: Cyclophosphamide 400 mg/m2 iv Doxorubicin 25 mg/m2 iv Vincristine 1 mg iv Rituximab 375 mg/m2 iv or sc Day 1-5: Prednisolone 100 mg po |
| Arm B: Epcoritamab-Pirtobrutinib | Experimental | Biological: Epcoritamab, Drug: Pirtobrutinib12 cycles: Cycle 1 Day 1-21: Pirtobrutinib 200 mg QD po Day 1: Epcoritamab 0.16 mg sc Day 8: Epcoritamab 0.8 mg sc Day 15: Epcoritamab 48 mg sc Cycle 2-4 Day 1-21: Pirtobrutinib 200 mg QD po Day 1, 8, 15: Epcoritamab 48 mg sc Cycle 5+6 Day 1-21: Pirtobrutinib 200 mg QD po Day 1: Epcoritamab 48 mg sc Cycle 7-12: Day 1-28: Pirtobrutinib 200 mg QD po Day 1: Epcoritamab 48 mg sc For patients with CR, PR or SD after 12 cycles (=EO[C]T), maintenance treatment with pirtobrutinib 200 mg QD until unacceptable toxicity, disease progression or allogeneic stem cell transplantation will be offered. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (17 listed)
- Age ≥80 years OR considered frail defined by a frailty score of >2 on the FRAIL scale via the patient´s assessment
- Has documented treatment-naïve CLL or small lymphocytic lymphoma (SLL) according to iwCLL 2018 criteria3
- CLL/SLL requiring treatment according to the iwCLL 2018 criteria3
- Adequate marrow function independent of growth factor or transfusion support within 2 weeks of screening as follows, unless cytopenia is due to marrow involvement of CLL:
- Adequate liver function as indicated by a total bilirubin, AST, and ALT ≤2 times the institutional upper limit of normal (ULN) value unless directly attributable to the patient's CLL or Gilbert's syndrome
Key exclusion criteria (9 listed)
- 1. Previous CLL-directed therapies 2. Transformation of CLL to aggressive NHL (Richter's transformation or pro-lymphocytic leu-kaemia) 3. Patients with a history of confirmed progressive multifocal leukoencephalopathy (PML) 4. Uncontrolled autoimmune condition 5. Malignancies other than CLL currently requiring systemic therapies (unless the malignant dis-ease is in a stable remission at the discretion of the treating physician) 6. Uncontrolled infection currently requiring systemic treatment 7. Any serious medical condition or abnormality in clinical laboratory tests that, in the investiga-tor's judgment, precludes the patient's safe participation in and completion of the study 8. Requirement of treatment with any moderate or strong CYP3A4 inhibitor or strong CYP3A4 inducer (≤ 14 days or 5 half-lives, whichever is shorter) before the first dose of study drug, or requiring ongoing treatment with a moderate or strong CYP3A inhibitor or a strong CYP3A in-ducer.
- 9. Requirement of therapy with phenprocoumon or other vitamin K antagonists 10. Known active infection with HIV, or serologic status reflecting active hepatitis B or C infection as follows:
- 15. Use of investigational agents, e.g. monoclonal antibodies or other experimental drugs within clinical trials, which might interfere with the study drug within 28 days (or 5 times half-life [t1/2] of the compound, whichever is longer) prior to registration 16. Known hypersensitivity to zanubrutinib or sonrotoclax or any of the excipients 17. Pregnant women and nursing mothers (a negative pregnancy test is required for all women of childbearing potential within 7 days before start of treatment) 18. Fertile men or women of childbearing potential unless:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EpcoritamabAlso: Epkinly®Cycle 1 Day 1-21: Pirtobrutinib 200 mg QD po Day 1: Epcoritamab 0.16 mg sc Day 8: Epcoritamab 0.8 mg sc Day 15: Epcoritamab 48 mg sc Cycle 2-28 Epcoritamab 48 mg sc | Biological | Arm B: Epcoritamab-Pirtobrutinib |
| PirtobrutinibAlso: Jaypirca®Pirtobrutinib 200 mg QD po | Drug | Arm B: Epcoritamab-Pirtobrutinib |
| Cyclophosphamide750 mg/m2 iv (R-CHOP) or 400 mg/m2 iv (R-mini-CHOP) | Drug | Arm A: R-(mini)-CHOP |
| Doxorubicin50 mg/m2 iv (R-CHOP) or 25 mg/m2 iv (R-mini-CHOP) | Drug | Arm A: R-(mini)-CHOP |
| Vincristine1.4 mg/m2 iv (R-CHOP) or 1 mg/m2 iv (R-mini-CHOP) | Drug | Arm A: R-(mini)-CHOP |
| Rituximab375 mg/m2 iv (R-CHOP) or 375 mg/m2 iv or sc (R-mini-CHOP) | Drug | Arm A: R-(mini)-CHOP |
Primary outcome
PFS
Time frame: approx. 40 months after first subject in
Investigator-assessed progression-free survival (PFS) according to Lugano criteria
9 secondary outcomes
ORR
Time frame: approx. 40 months after first subject in
CRR
Time frame: approx. 40 months after first subject in
Best response according to Lugano criteria
Time frame: approx. 40 months after first subject in
Undetectable minimal residual disease (uMRD)
Time frame: approx. 40 months after first subject in
DOR
Time frame: approx. 40 months after first subject in
Overall survival (OS)
Time frame: approx. 40 months after first subject in
TTNT
Time frame: approx. 40 months after first subject in
TFS
Time frame: approx. 40 months after first subject in
SCT
Time frame: approx. 40 months after first subject in
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2026.
Related trials for Richter Transformation
Active, not recruitingPhase 1/2
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Not yet recruitingPhase 1
huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Active, not recruitingPhase 1
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma
RecruitingPhase 2
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Chronic Lymphocytic Leukemia, Richter's Transformation
RecruitingPhase 1/2
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
B-cell Malignancy, Non-Hodgkin Lymphoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
12 sites in 5 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Epcoritamab, Pirtobrutinib and Cyclophosphamide in people with Richter Transformation, run by German CLL Study Group at 12 sites in 5 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 17 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 12 sites in Germany, Austria, Ireland, Australia, Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
PFS (time frame: approx. 40 months after first subject in). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2026.